The global spread of the novel coronavirus SARS-CoV-2 urgently requires discovery of effective therapeutics for the treatment of COVID-19. The spike (S) protein of SARS-CoV-2 plays a key role in receptor recognition, virus-cell membrane fusion and virus entry. Our previous studies have reported that 3-hydroxyphthalic anhydride-modified chicken ovalbumin (HP-OVA) serves as a viral entry inhibitor to prevent several kinds of virus infection. Here, our results reveal that HP-OVA can effectively inhibit SARS-CoV-2 replication and S protein-mediated cell-cell fusion in a dose-dependent manner without obvious cytopathic effects. Further analysis suggests that HP-OVA can bind to both the S protein of SARS-CoV-2 and host angiotensin-converting enzyme 2 (ACE2), the functional receptor of SARS-CoV-2, and disrupt the S protein-ACE2 interaction, thereby exhibiting inhibitory activity against SARS-CoV-2 infection. In summary, our findings suggest that HP-OVA can serve as a potential therapeutic agent for the treatment of deadly COVID-19.
【저자키워드】 SARS-CoV-2, spike, angiotensin-converting enzyme 2, fusion inhibitor, 3-hydroxyphthalic anhydride-modified chicken ovalbumin, 【초록키워드】 COVID-19, Treatment, ACE2, SARS-COV-2 infection, viral entry, Replication, Spread, Protein, therapeutic, virus entry, receptor, virus infection, cell-cell fusion, inhibitor, Interaction, Analysis, dose-dependent manner, novel coronavirus SARS-CoV-2, previous study, inhibitory activity, cytopathic effects, Host, Prevent, effective, virus-cell membrane fusion, reported, functional, the S protein, exhibiting, disrupt, inhibit SARS-CoV-2, ovalbumin, 【제목키워드】 ACE2, chicken, candidate, Potential,